Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Bevacizumab (Mvasi) for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar
(Final Biosimilar Dossier Issued as of January 14, 2019)

Pembrolizumab (Keytruda) for squamous Non-Small Cell Lung Cancer
(Pending Submission as of January 11, 2019)

Daratumumab (Darzalex) in combination with Bortezomib, Melphalan and Prednisone for Multiple Myeloma
(Open for Input on Submission until January 18, 2019)

Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma Resubmission
(Open for Input on Recommendation until January 18, 2019)

Nivolumab (Opdivo) for Melanoma Adjuvant Therapy
(Open for Input on Recommendation until January 18, 2019)

Lenvatinib (Lenvima) for Advanced Renal Cell Carcinoma
(Final Recommendation Issued as of January 4, 2019)

Osimertinib (Tagrisso) for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (first line) 
(Final Recommendation Issued as of January 4, 2019)

Lenvatinib (Lenvima) for Hepatocellular Carcinoma
(Pending Submission as of January 3, 2019)

Trifluridine-Tipiracil (Lonsurf) for Metastatic Colorectal Cancer - Resubmission
(Pending Submission as of December 14, 2018)

Brigatinib (Alunbrig) for Non-Small Cell Lung Cancer
(Open for Input on Submission until December 19, 2018)

Abiraterone (Zytiga) for Prostate Cancer
(Pending Submission as of November 27, 2018)

Find a Drug Review